Plitidepsin
- Generic Name
- Plitidepsin
- Drug Type
- Small Molecule
- Chemical Formula
- C57H87N7O15
- CAS Number
- 137219-37-5
- Unique Ingredient Identifier
- Y76ID234HW
- Background
Aplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatment for some leukemias.
- Indication
Intended for the treatment of various forms of cancer.
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
- Conditions
- Advanced Solid TumorsLymphomas
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2011-06-07
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 45
- Registration Number
- NCT00788099
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇺🇸The Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
- Conditions
- Relapsed/Refractory Leukemia
- Interventions
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 3
- Registration Number
- NCT00780143
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2009-12-24
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 51
- Registration Number
- NCT00229203
- Locations
- 🇺🇸
Jerome Lipper Multiple Myeloma Center - Dept of Medical Oncology - Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.